Share this article
Share this article
ResearchAndMarkets.com s offering.
The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5% during the forecast period.
Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand, the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.
The consumables segment accounted for the highest growth rate in the immuno-oncology assays market, by product & service, during the forecast period
Mexico
Japan
United-states
India
Brazil
China
Dublin
Ireland
Canada
America
Merck-millipore
Asia-pacific